Chiara Maria Teresa Boggio

Mrs. Chiara Maria Teresa Boggio

Università del Piemonte Orientale, Novara, Piedmont, Italy

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2025 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
Chiara Maria Teresa BoggioChiara Maria Teresa Boggio
Chiara Maria Teresa Boggio
Federica VeroneseFederica Veronese
Federica Veronese
Marta ArmariMarta Armari
Marta Armari
Elisa ZavattaroElisa Zavattaro
Elisa Zavattaro
EEElia Esposto
Elia Esposto
Barbara AzzimontiBarbara Azzimonti
Barbara Azzimonti
SUMMARY: Atopic dermatitis (AD) is a prevalent chronic inflammatory skin disorder, affecting 10%–20% of the population, characterized by dryness, intense itching, and recurrent rashes. The pathophysiology of AD is multifactorial, involving skin barrier dysfunction, immune dysregulation, genetic factors (such as filaggrin mutations), and environmental factors. The skin microbiota also plays a pivotal role in AD, serving both as a target and a driver of the disease. In AD, the delicate balance of the skin microbiota is disrupted, leading to a decrease in beneficial bacteria such as Streptococcus , Cutibacterium , and Corynebacterium . Concurrently, bacterial pathobionts, notably Staphylococcus aureus , proliferate and express their virulence factors excessively. This imbalance exacerbates symptoms by damaging the skin barrier, releasing toxins, and triggering a Th2-driven immune response, thus weakening the skin defenses and making individuals with AD more susceptible to bacterial, fungal, and viral infections, thereby complicating treatment and worsening disease outcomes. Effective AD management requires a thorough understanding of the interplay among the skin microbiota, the immune system, and microbial pathobionts. Strategies that restore the microbial balance, preserve the skin barrier, and modulate the immune response show significant potential for reducing infections and improving AD symptoms, highlighting the microbiota’s dual role in AD pathology. This review examines the complex role of the skin microbiota in AD, emphasizing how dysbiosis both drives disease progression and influences immune responses, and vice versa. It also explores emerging microbiota-targeted therapies aimed at improving disease outcomes.

25 March 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
Chiara Maria Teresa BoggioChiara Maria Teresa Boggio
Chiara Maria Teresa Boggio
Federica VeroneseFederica Veronese
Federica Veronese
Marta ArmariMarta Armari
Marta Armari
Elisa ZavattaroElisa Zavattaro
Elisa Zavattaro
EEElia Esposto
Elia Esposto
Barbara AzzimontiBarbara Azzimonti
Barbara Azzimonti
Atopic dermatitis (AD) is a chronic inflammatory skin disorder influenced by both genetic and environmental factors, collectively termed the exposome. Among these determinants, diet emerges as a pivotal component, with diverse nutrients, contaminants, and additives shaping immune responses, microbiota composition, and systemic inflammatory status. This literature review aimed to elucidate the interplay between dietary factors and skin dysbiosis in AD, providing insights into how these interactions may impact disease susceptibility and progression. A comprehensive search of PubMed and Scopus was conducted using relevant keywords and medical subject headings (MeSH). Studies published in English within the past 25 years were included, encompassing in vitro, in vivo, and ex vivo research, as well as reviews. Priority was given to frequently cited articles, reflecting significant contributions to current understanding. Findings suggest that dietary habits influence AD by modulating both gut and skin microbiota, immune pathways, and inflammatory processes. These insights underscore the importance of considering diet within a broader exposome framework, paving the way for targeted interventions to improve AD management. Further research is needed to clarify the mechanisms and optimize nutritional strategies, potentially informing preventive and therapeutic approaches for AD.

1 July 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Teresa GravinaTeresa Gravina
Teresa Gravina
Chiara Maria Teresa BoggioChiara Maria Teresa Boggio
Chiara Maria Teresa Boggio
EGElisa Gorla
Elisa Gorla
LRLuisa Racca
Luisa Racca
SPSilvia Polidoro
Silvia Polidoro
Gianluca BaldanziGianluca Baldanzi
Gianluca Baldanzi
Diacylglycerol kinases (DGKs) play dual roles in cell transformation and immunosurveillance. According to cancer expression databases, acute myeloid leukemia (AML) exhibits significant overexpression of multiple DGK isoforms, including DGKA, DGKD and DGKG, without a precise correlation with specific AML subtypes. In the TGCA database, high DGKA expression negatively correlates with survival, while high DGKG expression is associated with a more favorable prognosis. DGKA and DGKG also feature different patterns of co-expressed genes. Conversely, the BeatAML and TARGET databases show that high DGKH expression is correlated with shorter survival. To assess the suitability of DGKs as therapeutic targets, we treated HL-60 and HEL cells with DGK inhibitors and compared cell growth and survival with those of untransformed lymphocytes. We observed a specific sensitivity to R59022 and R59949, two poorly selective inhibitors, which promoted cytotoxicity and cell accumulation in the S phase in both cell lines. Conversely, the DGKA-specific inhibitors CU-3 and AMB639752 showed poor efficacy. These findings underscore the pivotal and isoform-specific involvement of DGKs in AML, offering a promising pathway for the identification of potential therapeutic targets. Notably, the DGKA and DGKH isoforms emerge as relevant players in AML pathogenesis, albeit DGKA inhibition alone seems insufficient to impair AML cell viability.

3 February 2026 in Journal of the American Academy of Dermatology
Verified
Journal Article
Open access
FVFederica Veronese
Federica Veronese
Chiara Maria Teresa BoggioChiara Maria Teresa Boggio
Chiara Maria Teresa Boggio
MAMarta Armari
Marta Armari
CAChiara Airoldi
Chiara Airoldi
EEElia Esposto
Elia Esposto
BABarbara Azzimonti
Barbara Azzimonti

5 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
BABarbara Azzimonti
Barbara Azzimonti
MLMoreno Lelli
Moreno Lelli
AJAlaa Jammoul
Alaa Jammoul
CAChiara Airoldi
Chiara Airoldi
Chiara Maria Teresa BoggioChiara Maria Teresa Boggio
Chiara Maria Teresa Boggio
AVAlessia Vignoli
Alessia Vignoli
Atopic dermatitis (AD) is a chronic inflammatory skin disease often requiring systemic biological therapies, such as the IL-4/IL-13 inhibitor Dupilumab, for long-term disease control. While Dupilumab is highly effective in restoring the skin barrier and reducing clinical severity, systemic complications may occur. We report a 62-year-old female with severe AD longitudinally monitored during Dupilumab treatment at baseline (T0), week 4 (T4), week 8 (T8), and week 16 (T16). Clinical assessments were performed at all visits, while microbiological, cytokine, metagenomic, and metabolomic analyses were conducted at T0, T8, and T16. The patient showed rapid clinical improvement at T4, followed by an abrupt transient worsening associated with an intercurrent S. aureus sepsis, and sustained improvement by T16, with EASI decreasing from 50.4 to 20. Despite the systemic inflammatory surge, no cutaneous relapse was documented. Multi-omics profiling highlighted a distinct immunological decoupling: while skin S. aureus load and type 2 inflammatory markers (IL-13, IL-31) progressively declined, a sharp surge in systemic pro-inflammatory cytokines (TNF-alpha) was observed at week 16, temporally associated with the septic episode. This case illustrates how longitudinal multi-omics profiling may uncover clinically silent systemic immune alterations that are not captured by conventional disease activity scores.